Skip to Main Content

Advertisement

Skip Nav Destination

Issues

Highlights

20th Anniversary Commentary

CCR Translations

CCR New Strategies

CCR Perspectives in Drug Approval

Molecular Pathways

Author Choice

Cancer Therapy: Clinical

Personalized Medicine and Imaging

Sharon E. Johnatty; on behalf of the Australian Ovarian Cancer Study Group; Jonathan P. Tyrer; on behalf of the Australian Ovarian Cancer Study Group; Siddhartha Kar; on behalf of the Australian Ovarian Cancer Study Group; Jonathan Beesley; on behalf of the Australian Ovarian Cancer Study Group; Yi Lu; on behalf of the Australian Ovarian Cancer Study Group; Bo Gao; on behalf of the Australian Ovarian Cancer Study Group; Peter A. Fasching; on behalf of the Australian Ovarian Cancer Study Group; Alexander Hein; on behalf of the Australian Ovarian Cancer Study Group; Arif B. Ekici; on behalf of the Australian Ovarian Cancer Study Group; Matthias W. Beckmann; on behalf of the Australian Ovarian Cancer Study Group; Diether Lambrechts; on behalf of the Australian Ovarian Cancer Study Group; Els Van Nieuwenhuysen; on behalf of the Australian Ovarian Cancer Study Group; Ignace Vergote; on behalf of the Australian Ovarian Cancer Study Group; Sandrina Lambrechts; on behalf of the Australian Ovarian Cancer Study Group; Mary Anne Rossing; on behalf of the Australian Ovarian Cancer Study Group; Jennifer A. Doherty; on behalf of the Australian Ovarian Cancer Study Group; Jenny Chang-Claude; on behalf of the Australian Ovarian Cancer Study Group; Francesmary Modugno; on behalf of the Australian Ovarian Cancer Study Group; Roberta B. Ness; on behalf of the Australian Ovarian Cancer Study Group; Kirsten B. Moysich; on behalf of the Australian Ovarian Cancer Study Group; Douglas A. Levine; on behalf of the Australian Ovarian Cancer Study Group; Lambertus A. Kiemeney; on behalf of the Australian Ovarian Cancer Study Group; Leon F.A.G. Massuger; on behalf of the Australian Ovarian Cancer Study Group; Jacek Gronwald; on behalf of the Australian Ovarian Cancer Study Group; Jan Lubiński; on behalf of the Australian Ovarian Cancer Study Group; Anna Jakubowska; on behalf of the Australian Ovarian Cancer Study Group; Cezary Cybulski; on behalf of the Australian Ovarian Cancer Study Group; Louise Brinton; on behalf of the Australian Ovarian Cancer Study Group; Jolanta Lissowska; on behalf of the Australian Ovarian Cancer Study Group; Nicolas Wentzensen; on behalf of the Australian Ovarian Cancer Study Group; Honglin Song; on behalf of the Australian Ovarian Cancer Study Group; Valerie Rhenius; on behalf of the Australian Ovarian Cancer Study Group; Ian Campbell; on behalf of the Australian Ovarian Cancer Study Group; Diana Eccles; on behalf of the Australian Ovarian Cancer Study Group; Weiva Sieh; on behalf of the Australian Ovarian Cancer Study Group; Alice S. Whittemore; on behalf of the Australian Ovarian Cancer Study Group; Valerie McGuire; on behalf of the Australian Ovarian Cancer Study Group; Joseph H. Rothstein; on behalf of the Australian Ovarian Cancer Study Group; Rebecca Sutphen; on behalf of the Australian Ovarian Cancer Study Group; Hoda Anton-Culver; on behalf of the Australian Ovarian Cancer Study Group; Argyrios Ziogas; on behalf of the Australian Ovarian Cancer Study Group; Simon A. Gayther; on behalf of the Australian Ovarian Cancer Study Group; Aleksandra Gentry-Maharaj; on behalf of the Australian Ovarian Cancer Study Group; Usha Menon; on behalf of the Australian Ovarian Cancer Study Group; Susan J. Ramus; on behalf of the Australian Ovarian Cancer Study Group; Celeste L. Pearce; on behalf of the Australian Ovarian Cancer Study Group; Malcolm C. Pike; on behalf of the Australian Ovarian Cancer Study Group; Daniel O. Stram; on behalf of the Australian Ovarian Cancer Study Group; Anna H. Wu; on behalf of the Australian Ovarian Cancer Study Group; Jolanta Kupryjanczyk; on behalf of the Australian Ovarian Cancer Study Group; Agnieszka Dansonka-Mieszkowska; on behalf of the Australian Ovarian Cancer Study Group; Iwona K. Rzepecka; on behalf of the Australian Ovarian Cancer Study Group; Beata Spiewankiewicz; on behalf of the Australian Ovarian Cancer Study Group; Marc T. Goodman; on behalf of the Australian Ovarian Cancer Study Group; Lynne R. Wilkens; on behalf of the Australian Ovarian Cancer Study Group; Michael E. Carney; on behalf of the Australian Ovarian Cancer Study Group; Pamela J. Thompson; on behalf of the Australian Ovarian Cancer Study Group; Florian Heitz; on behalf of the Australian Ovarian Cancer Study Group; Andreas du Bois; on behalf of the Australian Ovarian Cancer Study Group; Ira Schwaab; on behalf of the Australian Ovarian Cancer Study Group; Philipp Harter; on behalf of the Australian Ovarian Cancer Study Group; Jacobus Pisterer; on behalf of the Australian Ovarian Cancer Study Group; Peter Hillemanns; on behalf of the Australian Ovarian Cancer Study Group; on behalf of the AGO Study Group; Beth Y. Karlan; on behalf of the Australian Ovarian Cancer Study Group; Christine Walsh; on behalf of the Australian Ovarian Cancer Study Group; Jenny Lester; on behalf of the Australian Ovarian Cancer Study Group; Sandra Orsulic; on behalf of the Australian Ovarian Cancer Study Group; Stacey J. Winham; on behalf of the Australian Ovarian Cancer Study Group; Madalene Earp; on behalf of the Australian Ovarian Cancer Study Group; Melissa C. Larson; on behalf of the Australian Ovarian Cancer Study Group; Zachary C. Fogarty; on behalf of the Australian Ovarian Cancer Study Group; Estrid Høgdall; on behalf of the Australian Ovarian Cancer Study Group; Allan Jensen; on behalf of the Australian Ovarian Cancer Study Group; Susanne Kruger Kjaer; on behalf of the Australian Ovarian Cancer Study Group; Brooke L. Fridley; on behalf of the Australian Ovarian Cancer Study Group; Julie M. Cunningham; on behalf of the Australian Ovarian Cancer Study Group; Robert A. Vierkant; on behalf of the Australian Ovarian Cancer Study Group; Joellen M. Schildkraut; on behalf of the Australian Ovarian Cancer Study Group; Edwin S. Iversen; on behalf of the Australian Ovarian Cancer Study Group; Kathryn L. Terry; on behalf of the Australian Ovarian Cancer Study Group; Daniel W. Cramer; on behalf of the Australian Ovarian Cancer Study Group; Elisa V. Bandera; on behalf of the Australian Ovarian Cancer Study Group; Irene Orlow; on behalf of the Australian Ovarian Cancer Study Group; Tanja Pejovic; on behalf of the Australian Ovarian Cancer Study Group; Yukie Bean; on behalf of the Australian Ovarian Cancer Study Group; Claus Høgdall; on behalf of the Australian Ovarian Cancer Study Group; Lene Lundvall; on behalf of the Australian Ovarian Cancer Study Group; Ian McNeish; on behalf of the Australian Ovarian Cancer Study Group; James Paul; on behalf of the Australian Ovarian Cancer Study Group; Karen Carty; on behalf of the Australian Ovarian Cancer Study Group; Nadeem Siddiqui; on behalf of the Australian Ovarian Cancer Study Group; Rosalind Glasspool; on behalf of the Australian Ovarian Cancer Study Group; Thomas Sellers; on behalf of the Australian Ovarian Cancer Study Group; Catherine Kennedy; on behalf of the Australian Ovarian Cancer Study Group; Yoke-Eng Chiew; on behalf of the Australian Ovarian Cancer Study Group; Andrew Berchuck; on behalf of the Australian Ovarian Cancer Study Group; Stuart MacGregor; on behalf of the Australian Ovarian Cancer Study Group; Paul D.P. Pharoah; on behalf of the Australian Ovarian Cancer Study Group; Ellen L. Goode; on behalf of the Australian Ovarian Cancer Study Group; Anna deFazio; on behalf of the Australian Ovarian Cancer Study Group; Penelope M. Webb; on behalf of the Australian Ovarian Cancer Study Group; Georgia Chenevix-Trench; on behalf of the Australian Ovarian Cancer Study Group
Frank A. Sinicrope; for the Alliance for Clinical Trials in Oncology; Michelle R. Mahoney; for the Alliance for Clinical Trials in Oncology; Harry H. Yoon; for the Alliance for Clinical Trials in Oncology; Thomas C. Smyrk; for the Alliance for Clinical Trials in Oncology; Stephen N. Thibodeau; for the Alliance for Clinical Trials in Oncology; Richard M. Goldberg; for the Alliance for Clinical Trials in Oncology; Garth D. Nelson; for the Alliance for Clinical Trials in Oncology; Daniel J. Sargent; for the Alliance for Clinical Trials in Oncology; Steven R. Alberts; for the Alliance for Clinical Trials in Oncology

Cancer Therapy: Preclinical

Author Choice
Author Choice

Biology of Human Tumors

Author Choice

Letter to the Editor

or Create an Account

Close Modal
Close Modal